Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vor Biopharma Inc VOR

Healthcare Biotechnology
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development... see more

Recent & Breaking News (NDAQ:VOR)

First AML Patient Transplanted with Vor Bio's Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg(TM) Cycles at Initial Dose Level

GlobeNewswire February 16, 2023

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

GlobeNewswire January 19, 2023

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

GlobeNewswire January 12, 2023

Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million

GlobeNewswire December 7, 2022

First AML Patient Successfully Transplanted with Vor Bio's Investigational Trem-cel (VOR33) and Tolerated Mylotarg(TM)

GlobeNewswire December 7, 2022

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire November 22, 2022

Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update

GlobeNewswire November 10, 2022

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire November 1, 2022

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer

GlobeNewswire October 12, 2022

Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment

GlobeNewswire October 11, 2022

Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters

GlobeNewswire September 28, 2022

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire September 6, 2022

Vor Bio Reports Second Quarter 2022 Financial Results and Provides Company Update

GlobeNewswire August 11, 2022

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire August 1, 2022

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

GlobeNewswire June 10, 2022

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire June 1, 2022

Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

GlobeNewswire May 12, 2022

Vor to Participate in Two Upcoming Investor Conferences

GlobeNewswire May 5, 2022

Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

GlobeNewswire April 25, 2022

Vor Bio Announces Retirement of Chief Medical Officer

GlobeNewswire April 14, 2022